Publications dans lesquelles il/elle collabore avec José López Aldeguer (14)

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  2. HTLV testing of solid organ transplant donors

    Clinical Transplantation

  3. HTLV-1 infection in solid organ transplant donors and recipients in Spain

    BMC Infectious Diseases, Vol. 19, Núm. 1

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  3. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  4. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

2007

  1. Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain

    Medicina Clinica

2001

  1. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy

    HIV Clinical Trials, Vol. 2, Núm. 5, pp. 429-437